Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (13239)	9/30/2004 2:16:52 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

DOVP could be a beneficiary I assume because of bicifadine? The issue is to what extent the cox-2 drugs are used in pure pain conditions vs. mixed pain/inflammatory conditions. Not clear how well bicifadine will work in arthritis pain. (But I own DOVP, so I'm happy for Feuerstein to be plugging it). Incidentally there is a topical NSAID (topical ketoprofen - Orudis) that is available OTC outside the US. (I buy it over the internet). It's absolutely magical for localised muscle and joint pain - works virtually instantly. Some systemic absorption, so not risk-free, but small compared to oral. Photosensitivity reactions are a problem (maybe 1 in a 1,000) - probably why it's not available in the US). Peter